Modera and Merck report Phase 3 melanoma vaccine cuts recurrence risk, stock surges

Pharmaceutical companies Moderna and Merck announced on August 19, 2026, that a Phase 3 clinical trial of their personalized mRNA cancer vaccine successfully met its primary goals, significantly reducing the risk of melanoma recurrence and spread in high-risk patients.